USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

December 11, 2018PR-M12-18-NI-033

Increasing Market Demand for Regenerative Therapies Drives Diversification

SUNRISE, Fla./PRNewswire/ -- U.S. Stem Cell, Inc., a leader in regenerative medicine products and services, today announced its three partially owned Florida-based clinics have expanded their menu of services to help meet the growing market demand and patient needs for regenerative therapies.

In addition to continuing to offer targeted stem cell therapies of all kinds -- bone marrow, adipose, and tissue bank products -- U.S. Stem Cell Clinic is also providing regenerative therapies outside the stem cell space, including platelet rich plasma (PRP), IV nutritionals, infrared therapy, electromagnetic pulsed wave therapy, ozone therapy, diet and nutritional counseling and other services designed to promote regeneration and natural healing.

"We are living in a historic time where we are witnessing the emergence of stem cell therapy as a rapidly growing modality that will soon become standard of care in modern medicine," said Mike Tomas, President and CEO of U.S. Stem Cell, Inc.  "Because we are an industry leader in bringing regenerative medicine therapies to the marketplace in a clinical setting, and because we know cutting-edge therapies can take time to be fully understood and endorsed, it is important for us to maintain a portfolio of proven products and services each patient can choose from based on his or her own needs. It's good business and it's good medicine."

"The opportunity to be a part of history at a time when we are witnessing an incredible paradigm shift in the use of stem cell therapy is monumental," said Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell Clinic's parent company, U.S. Stem Cell, Inc.  "All advancements in science require time.  By diversifying our regenerative medicine offerings, we are moving through this very important time in medicine while simultaneously making sure our customers continue to have a variety of safe and effective options for their care that will empower them to choose the product and/or service they feel is right for them."

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at

Media Contact: U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Phone: 954.835.1500

chat button